Clinical Trial Update: Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase II trial of Doxil (liposomal doxorubicin), carboplatin, and bevacizumab in untreated metastatic breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Doxil (liposomal doxorubicin)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-02-08